Encora CEO Shift Sparks Pipeline Surge

🚀 Battle Card: Encora Therapeutics

• Nadim Yared, Chairman and Chief Executive Officer · 🔗 [LinkedIn](https://www.linkedin.com/company/encora-therapeutics/)

• This Encora Therapeutics sales trigger highlights a leadership shift toward scaling late-stage clinical programs and commercial pathways, driving urgency for evidence-generation and reimbursement strategies. → Source

• Need for rigorous clinical evidence to satisfy regulators and payers

• Lack of scalable reimbursement and market-access models for neuromodulation devices

• Primary: Clinical Evidence Platform → Accelerate trial completion and data submission

• Expansion: Reimbursement & RWE Solutions → Optimize coverage and patient access

• HQ: Boston, MA

• Employees: ≈ 70

• Rev: ≈ $10 M

• Website: [encoratherapeutics.com](https://encoratherapeutics.com/)

🤼 Competitive Intel

• Medtronic (medtronic.com) — Neuromodulation systems
• Unique edge: Broad clinical installed base in movement disorders
• Evaluated by VP Ops & Dir. Clinical for legacy support

• Abbott (abbott.com) — Deep brain stimulation platforms
• Unique edge: Integrated software for patient monitoring
• Evaluated by Dir. Regulatory for compliance track record

• Boston Scientific (bostonscientific.com) — Non-invasive neuromodulation
• Unique edge: Strong reimbursement playbook in neuro
• Evaluated by CFO & VP Marketing for cost forecast

✅ Do-Now Checklist

Next Step

🧠 Copy My Prompt for Personalized Cold Outreach

────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY   = ❑≈ TBD❑
OFFER_BRIEF   = ❑our Clinical Evidence Platform❑
PROOF_METRIC  = ❑30% faster trial completion❑
CTA_STYLE     = ❑quick_call❑
TONE          = ❑friendly❑

────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME        = Nadim
COMPANY     = Encora Therapeutics
DEPT        = Clinical
SIZE        = ≈10
BOTTLENECK  = regulatory and reimbursement hurdles
EVENT       = leadership change
DETAIL      = Names Nadim Yared as Chairman and Chief Executive Officer
PAIN        = Need for rigorous clinical evidence to satisfy regulators and payers
SRC         = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20251002069283&div=41152219
SIM_CO      = CVRx
WIN_METRIC  = 30% faster trial completion
NEXT_SIZE   = ≈20
EMP_EST     = ≈70
REV_EST     = ≈$10M

────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.

Validate any ≈ guesses via SRC.

EMAIL  (keep breaks):
Subject: ≈10-person Clinical

Nadim—noticed your Clinical team is ≈ 10.

That’s when regulatory and reimbursement hurdles slows growth.

We helped CVRx fix this with our Clinical Evidence Platform.

Result: 30% faster trial completion.  
Quick call?

PS—next bottleneck hits ≈ 20.

DM ≤45 words, TONE:
Saw your post about Names Nadim Yared as Chairman and Chief Executive Officer — Need for rigorous clinical evidence to satisfy regulators and payers.  
our Clinical Evidence Platform. 30% faster trial completion.  
Quick chat?